UBS has given Novartis a "Buy" rating and set a price target of 111 Swiss francs based on insights from a recent conference.
CFO Harry Kirsch expressed optimism about the company's growth prospects for 2025, coinciding with the expiration of the Entresto patent.
Analyst Matthew Weston highlighted this confidence in a report released on November 14, 2024. The report emphasizes UBS's positive outlook on Novartis, suggesting that the company is well-positioned to navigate patent expirations while driving growth. The analysis reflects a broader confidence in Novartis's strategic direction and market performance.